

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

CFN: 1125691  
Facility ID: 221617  
Inspection ID #2216170002



Food and Drug Administration  
Baltimore District Office  
900 Madison Avenue  
Baltimore, MD 21201-2199  
Telephone: (410) 962-3396

May 19, 2000

**WARNING LETTER****CERTIFIED MAIL**  
**RETURN RECEIPT REQUESTED**

Marilyn Muerdter, CMS Administrator  
Fluvanna Correctional Center for Women  
Route 250 West  
Troy, Virginia 22974

Dear Ms. Muerdter:

A representative from the Commonwealth of Virginia under contract to the Food and Drug Administration (FDA) inspected your facility on April 25, 2000. This inspection revealed a serious regulatory problem involving mammography performed at your facility.

Under a United States Federal law, the Mammography Quality Standards Act (MQSA) of 1992, your facility must meet specific requirements for mammography. These requirements help protect the public health by assuring that a facility can perform quality mammography. The inspection revealed the following Level 1 finding:

- **There is no system in place to provide patients with timely lay summaries of mammographic exam results.**

The specific problem noted above appeared on your MQSA Facility Inspection Report, which was issued to your facility at the close of the inspection. This problem is identified as a Level 1 finding because it identifies a failure to comply with a significant MQSA requirement.

Because this condition may be symptomatic of serious underlying problems that could compromise the quality of mammography performed at your facility, it represents a violation of the law that may result in FDA taking regulatory action without further notice to you.

These actions include, but are not limited to: placing your facility under a Directed Plan of Correction; charging your facility for the cost of on-site monitoring; assessing civil money penalties up to \$10,000 for each failure to substantially comply with, or each day of failure to substantially comply with MQSA standards; suspension or revocation of your facility's FDA certificate; or obtaining a court injunction against further mammography.

In addition, the following ~~Level 2 finding~~ was listed on the inspection report provided to you at the close of the inspection:

- **There is no written procedure for handling consumer complaints related to your mammography program.**

It is necessary for you to act on these matters immediately. Please address the Level 1 and Level 2 findings in a response to this office in writing within fifteen (15) working days from the date you receive this letter. Your response must describe:

- The specific steps you have taken to correct the violations noted in this letter.
- Each step your facility is taking to prevent the recurrence of similar violations.

Your response should be submitted to:

Food and Drug Administration  
900 Madison Avenue  
Baltimore, Maryland 21201  
Attn: Nancy L. Rose  
Compliance Officer

Finally, you should understand that there are many FDA requirements pertaining to mammography. This letter pertains only to findings of your inspection and does not necessarily address other obligations you may have under the law. You may obtain general information about all of FDA's requirements for mammography facilities by contacting the Mammography Quality Assurance Program, Food and Drug Administration, P.O. Box 6057, Columbia, MD 21045-6057 (1-800-838-7715), or through the Internet at <http://www.fda.gov>.

If you have technical questions about mammography facility requirements, or about the content of this letter, please feel free to contact Elizabeth A. Laudig at (410) 962-3591, extension 159.

Sincerely;



Lee Bowers  
Director, Baltimore District